Genmab — December 2024
-
AbbVie, Genmab tout Epkinly combos in earlier lines of non-Hodgkin lymphoma https://endpts.com/ash24-abbvie-genmab-tout-epkinly-combination-in-earlier-lines-of-non-hodgkin-lymphoma/
-
"Epkinly plus R-CHOP is being tested in an ongoing Phase 3 trial in the first-line setting. Allam Fakhoury, AbbVie’s therapeutic area lead in hematology oncology, told Endpoints News that the Phase 3 study in DLBCL is fully enrolled, and the company is “evaluating when the readout will be.” "
-
Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma https://www.youtube.com/watch?v=bTNyW_82_Ks
-
0:15 / 1:07
Evaluating whether prior bendamustine exposure impacts the efficacy of epcoritamab in DLBCL https://www.youtube.com/watch?v=MFJdK1oXTns
-
@calliecoombsmd
Much lower severity CRS when using optimized schedule of epcoritamab and with promising response data - high rates of CR and uMRD! Median PFS 12.8 months. https://x.com/calliecoombsmd/status/1866254711781028086 -
-
@OncLive
·
10 u
Epcoritamab monotherapy in patients aged >75 with DLBCL who were anthracycline ineligible resulted in ORR 69% (CR 62%) with durable responses. https://x.com/OncLive/status/1866261702074941460 https://x.com/Fer_martinmoro/status/1866262621726576992 -
a bit of a repeat - City of Hope Reports Novel Immunotherapy in Clinical Trial Shows Promise for Patients With Relapsed or Difficult to Treat Chronic Lymphocytic Leukemia (CLL) - https://www.businesswire.com/news/home/20241208552895/en/City-of-Hope-Reports-Novel-Immunotherapy-in-Clinical-Trial-Shows-Promise-for-Patients-With-Relapsed-or-Difficult-to-Treat-Chronic-Lymphocytic-Leukemia-CLL
-
Genmab leverer igen lovende data fra kræfthåb https://proinvestor.com/investornyt/1251772/genmab-leverer-igen-lovende-data-fra-kraefthab
-
https://www.biospace.com/drug-development/gsk-touts-42-survival-benefit-for-blenrep-in-multiple-myeloma-strengthening-bid-for-market-return?_gl=1*10oq5ns*_up*MQ.._gaMzc1NzEzMDI4LjE3MzM4NDI3NDA._ga_Q90M6MWJZ4MTczMzg0MjczOC4xLjAuMTczMzg0MjczOC4wLjAuMA..
-
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.
BioSpace (www.biospace.com)
-
Evaluate Pharma forecast Darzalex 2025 $13.17bn https://x.com/NatRevDrugDisc/status/1866496363371941939
-
jeg bliver altid så glad når Nohope skriver herinde. Det minder mig om, at der er plads til alle bidrag.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind